Covid, Perno: “‘Universal’ monoclonal sotrovimab against variants”

(Adnkronos) – On the occasion of the meeting “mAbs in the Early Treatment. Controversies and consensus in the fragile patient with Covid-19: we do not create antibodies”, promoted in Rome by GlaxoSmithKline and dedicated to the discussion of the best treatment options for fragile patients who contract Covid-19, spoke Carlo Federico Perno, director of microbiology and immunology diagnostics at the Bambin Gesù pediatric hospital in Rome.